Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial.

ABSTRACT:

Introduction

Galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, is a preventive migraine treatment. In global, randomized, placebo-controlled trials, galcanezumab reduced migraine headache severity and the frequency of migraine headaches associated with nausea and/or vomiting, photophobia and phonophobia, prodromal symptoms, or aura. We report secondary analyses from a Japanese phase 2 trial that assessed the effect of galcanezumab on migraine headache severity, frequency of migraine-associated symptoms, and frequency of migraine headaches during menstrual periods in Japanese patients with episodic migraine.

Methods

Adults with migraine (International Classification of Headache Disorders, 3rd edition; 4-14 migraine headache days/month) wer

SUBMITTER: Igarashi H 

PROVIDER: S-EPMC9837349 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature